Company Focused on Organic Growth with International Strategic Partnerships
HALIFAX, NS, Feb. 4 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2010 Annual General Meeting of Shareholders, which was held on January 28th, 2010. Dr. James Smith, Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. André Archimbaud were joined by Mr. Markus Meile, CEO of Vitest AG, as directors of the Company.
"Our Board is very much looking forward to the coming year," said Dr. James Smith, chairman of the Board of Directors. "Over the past twelve months, we have increased the strength of our Board as a whole, through the extensive experience of its individual members, particularly in the diagnostic industry, international business and medical fields. Our new Board is fully supportive of the Company's management team and its go-forward strategy. On behalf of MedMira, I extend a welcome to all re-elected members and Mr. Meile to our team."
Dr. Smith continued, "The Company's strategic plan is one of organic growth through the development and commercialization of new products and technologies based on our proven and patented diagnostic technology platform. In addition to this, our Partnership Investment Program is focused on identifying and nurturing key strategic partnerships with on-the-ground resources and connections within the global marketplace. This strategy has been proven to be a critical component of our success so far, and we look forward to realizing further progress through positive financial results in the upcoming quarters."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
For further information: For further information: Andrea Young, MedMira, (902) 450-1588, email@example.com